Peptide basics
Four unapproved GLP-1 compounds have already enrolled 65,000 people
On this page
Retatrutide, cagrilintide, survodutide and mazdutide are all in late-stage development and none has an FDA-approved product.
Their trial records are already substantial: 26,015 participants for retatrutide, 23,728 for cagrilintide, 12,628 for survodutide and 3,143 for mazdutide.
That is roughly 65,500 people across four unapproved compounds.
Being in phase 3 means the large trials are running or complete. It does not mean approval will follow.
This page describes the current trial record for four GLP-1-class compounds in late-stage development. None is approved. Nothing here predicts approval, recommends anything, or contains a dose, schedule or route.
The four records
- Retatrutide: 20 verified trials, 26,015 participants.
- Cagrilintide: 39 verified trials, 23,728 participants.
- Survodutide: 23 verified trials, 12,628 participants.
- Mazdutide: 12 verified trials, 3,143 participants.234
For comparison, tesamorelin has an FDA-approved product and 951 participants across its 18 trials. Three of these four unapproved compounds have more than ten times that.234
What a phase 3 record looks like up close
TRIUMPH-1 is a good example. It is a phase 3 randomised double-masked study of retatrutide that enrolled 2,335 adults, started on 10 July 2023, and has a primary completion date of 6 April 2026.1
That last date matters. A trial with a completion date in the near future has not reported its primary outcome, so anything circulating about its results is either from an earlier trial or is not from a trial at all.1
Why phase 3 is not a prediction
Reaching phase 3 means a sponsor judged the earlier results promising enough to fund a large trial. It is a meaningful signal about what a company believed, and it is not a result.2
Compounds fail at phase 3 regularly, and others succeed and are never marketed. This site records what the registry holds and does not forecast what regulators will do with it.2
Common questions
Can I obtain these compounds now?
Not as approved medicines — none of them is one. Material sold under these names outside a trial is not from the regulated supply chain and has not been reviewed by anyone.
Why does cagrilintide have so many trials?
It is studied both alone and in combination with semaglutide, and combination programmes generate more registered studies than single-compound ones.
When will results be public?
Each registry record carries its own completion date and results are posted or published after that. The record is the place to check rather than a news article.
Sources
- Primary studyTRIUMPH-1 (NCT05929066) — retatrutide phase 3 registry recordClinicalTrials.gov, U.S. National Library of Medicine, 2026clinicaltrials.gov/study/NCT05929066 ↗↩ Back to text
- RegulatoryClinicalTrials.gov search — intervention: retatrutideU.S. National Library of Medicine, 2026clinicaltrials.gov/search?intr=retatrutide ↗↩ Back to text
- RegulatoryClinicalTrials.gov search — intervention: cagrilintideU.S. National Library of Medicine, 2026clinicaltrials.gov/search?intr=cagrilintide ↗↩ Back to text
- RegulatoryClinicalTrials.gov search — intervention: survodutideU.S. National Library of Medicine, 2026clinicaltrials.gov/search?intr=survodutide ↗↩ Back to text